Evidence map›Paper›PMID 26136073›Full record

ArticlePloS one2015

Non-Muscle Myosin II Isoforms Have Different Functions in Matrix Rearrangement by MDA-MB-231 Cells.

Bridget Hindman, Zoe Goeckeler, Kostas Sierros, Robert Wysolmerski

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Non-Muscle Myosin II A: Friend or Foe in Cancer?International journal of molecular sciences · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bridget HindmanMary Babb Randolph Cancer Center, West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia, United States of America.
Zoe GoeckelerCenter for Cardiovascular and Respiratory Diseases, West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia, United States of America.
Kostas SierrosMechanical and Aerospace Engineering, Statler College of Engineering and Mineral Resources, West Virginia University, Morgantown, West Virginia, United States of America.
Robert WysolmerskiMary Babb Randolph Cancer Center, West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia, United States of America; Center for Cardiovascular and Respiratory Diseases, West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia, United States of America.
West Virginia University · US

Funding

THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8M
COBRE Transitional Center in NeuroscienceP30GM103503 · NIGMS · WEST VIRGINIA UNIVERSITY · PI SPIROU, GEORGE A · 2012 to 2014
$3.2M
TRANSGENIC ANIMAL COREP30RR031155 · NCRR · WEST VIRGINIA UNIVERSITY · PI SPIROU, GEORGE A · 2010 to 2011
$2.8M
Research Training in Cardiovascular and Pulmonary DiseasesT32HL090610 · NHLBI · WEST VIRGINIA UNIVERSITY · PI MUSTAFA, S. JAMAL · 2008 to 2012
$1.5M
NCRR NIH HHS P20 RR016440NCRR NIH HHS P20RR016440NCRR NIH HHS P30 RR031155NCRR NIH HHS P30RR031155NHLBI NIH HHS T32 HL090610NIGMS NIH HHS P30 GM103488NIGMS NIH HHS P30GM103488NIGMS NIH HHS P30 GM103503NIGMS NIH HHS P30GM103503
6 · The paper itself

Abstract

The role of a stiffening extra-cellular matrix (ECM) in cancer progression is documented but poorly understood. Here we use a conditioning protocol to test the role of nonmuscle myosin II isoforms in cell mediated ECM arrangement using collagen constructs seeded with breast cancer cells expressing shRNA targeted to either the IIA or IIB heavy chain isoform. While there are several methods available to measure changes in the biophysical characteristics of the ECM, we wanted to use a method which allows for the measurement of global stiffness changes as well as a dynamic response from the sample over time. The conditioning protocol used allows the direct measurement of ECM stiffness. Using various treatments, it is possible to determine the contribution of various construct and cellular components to the overall construct stiffness. Using this assay, we show that both the IIA and IIB isoforms are necessary for efficient matrix remodeling by MDA-MB-231 breast cancer cells, as loss of either isoform changes the stiffness of the collagen constructs as measured using our conditioning protocol. Constructs containing only collagen had an elastic modulus of 0.40 Pascals (Pa), parental MDA-MB-231 constructs had an elastic modulus of 9.22 Pa, while IIA and IIB KD constructs had moduli of 3.42 and 7.20 Pa, respectively. We also calculated the cell and matrix contributions to the overall sample elastic modulus. Loss of either myosin isoform resulted in decreased cell stiffness, as well as a decrease in the stiffness of the cell-altered collagen matrices. While the total construct modulus for the IIB KD cells was lower than that of the parental cells, the IIB KD cell-altered matrices actually had a higher elastic modulus than the parental cell-altered matrices (4.73 versus 4.38 Pa). These results indicate that the IIA and IIB heavy chains play distinct and non-redundant roles in matrix remodeling.

Indexed as

Breast NeoplasmsCell Line, TumorCell MovementCell ProliferationCollagenDNAElastic ModulusExtracellular MatrixFemaleHEK293 CellsHumansMicroscopy, FluorescenceNonmuscle Myosin Type IIANonmuscle Myosin Type IIBRNA, Small InterferingStress, MechanicalCollagenDNANonmuscle Myosin Type IIANonmuscle Myosin Type IIBRNA, Small Interfering

Identifiers

PMID26136073
PMCPMC4489869
OpenAlexW816649631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.